← SynDRA
NILOTINIB
SynDRA canonical compound SYN0008885 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | BCR |
|---|
| Mechanism of action | Abl kinase inhibitor |
|---|
| Indication | chronic myeloid leukemia (CML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- ABL1
- BCR
- KIT
- DDR1
- DDR2
- PDGFRA
- ABCG2
- MAP4K1
- MAP3K20
- MAP2K5
- LYN
- LCK
Mechanisms of action (all sources)
- Abl kinase inhibitor
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- BCR INHIBITOR
- DDR1 INHIBITOR
- DDR2 INHIBITOR
- Bcr-Abl kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA3
- SYK
- SLC22A3
- SLC29A1
- CYP3A4
- CACNA1C
- TACR1
- OPRK1
- PHKG1
- PDE3A
- PGR
- PI4KB
- PFKP
- PEBP1
- PDXK
- PDPK1
- PDE6A
- PDE4D
- PGRMC1
- AAK1
- PASK
- PIK3C2G
- PAK6
- PAK5
- PAK4
- PAK3
- PAK2
- PAK1
- PAICS
- OXSR1
- OPRM1
- OPRD1
- PIK3C2B
- PIK3CA
- OLA1
- PIK3CB
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- CACNA1D
- CACNA1F
- CACNA1S
- IFNG
- KSYK
- LDLR
- NSD2
- PCSK9
- TP53
Drug classes
- Bcr-Abl Tyrosine Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2D6 Inhibitors
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C8 Inhibitors
- Cytochrome P450 2C8 Inducers
- Cytochrome P450 2B6 Inducers
- UGT1A1 Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- CAVHANZA
- DANZITEN
- Danziten
- NILOTINIB D-TARTRATE
- NILOTINIB HYDROCHLORIDE
- TASIGNA
- Tasigna
- nilotinib hydrochloride hydrate
- tasigna
- nilotinib hydrochloride monohydrate
- AMN-107
- AMN107
- NSC-747599
- NIL
- Nilotinibum
- Tasigna (Novartis)
- Nilotinib (INN/USAN)
- Nilotinib, AMN107, Tasigna
- Tasigna, AMN-107, Nilotinib
- L-1-yl)-3-(trifluoromethyl)phenyl]benzamide
- Nilotinib (BCR-ABL inhibitor 2nd gen)
- Nilotinib free base
- Nilotinib (AMN-107)
- MFCD09833716
- NSC 747599
- CHEMBL255863
- CHEBI:52172
- 641571-10-0 (free base)
- NSC747599
- F41401512X
- Nilotinib & its intermediates
- nilotinibum
- Nilotinib(AMN-107)
- SMR002544680
- Nilotinib [USAN]
- Nilotinib [USAN:INN:BAN]
- HSDB 7842
- UNII-F41401512X
Reported adverse events
- Sudden death
- QT interval
- Abdominal pain
- Abdominal pain upper
- Alopecia
- Arthralgia
- Asthenia
- Back pain
- Bone pain
- Constipation
- Cough
- Death
Look up NILOTINIB in the interactive SynDRA portal →